Schlusskurs
Andere Börsenplätze
|
||
- USD | - |
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Matthew Pauls
CEO | Chief Executive Officer | 53 | 27.04.17 |
David Lowrance
DFI | Director of Finance/CFO | 56 | 27.04.17 |
Robert M. Lutz
COO | Chief Operating Officer | 55 | 13.02.23 |
Raymond Pratt
CTO | Chief Tech/Sci/R&D Officer | 73 | 10.11.22 |
Anne Erickson
IRC | Investor Relations Contact | - | 01.10.18 |
Charles LaPree
LAW | General Counsel | - | 01.08.21 |
Kate McCabe
LAW | General Counsel | - | 01.03.18 |
Scott Wilhoit
PRN | Corporate Officer/Principal | 61 | 09.01.23 |
Peter M. Clarke
PRN | Corporate Officer/Principal | 64 | 01.09.21 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
David Ramsay
BRD | Director/Board Member | 59 | 27.04.17 |
Richard Hawkins
BRD | Director/Board Member | 75 | 01.10.10 |
Nevan Elam
BRD | Director/Board Member | 56 | 01.02.09 |
Ricky Sun
BRD | Director/Board Member | 50 | 24.12.19 |
Joseph McCracken
BRD | Director/Board Member | 71 | 27.04.17 |
Matthew Pauls
CEO | Chief Executive Officer | 53 | 27.04.17 |
Director/Board Member | 64 | 03.12.19 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 138 188 891 | 130 399 382 ( 94,36 %) | 0 | 94,36 % |
Unternehmenskontakt
Savara, Inc.
1717 Langhorne Newtown Road Suite 302
19047, Langhorne
+(512) 614-1848
http://www.savarapharma.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+3.91% | 109 Mrd. | |
+10.87% | 105 Mrd. | |
+1.28% | 22.25 Mrd. | |
-13.14% | 22.09 Mrd. | |
-7.05% | 18.68 Mrd. | |
-38.36% | 17.58 Mrd. | |
-10.66% | 16.85 Mrd. | |
+3.75% | 13.76 Mrd. | |
+36.70% | 12.46 Mrd. |
- Börse
- Aktien
- A2DQ2B Aktie
- Aktie
- Unternehmen Savara Inc